News>
Alvotech posts H1 net loss as manufacturing, quality upgrades curb product revenue, company says
- For the six months ended June 30, 2026, net loss totaled USD 65.79 million, swinging from profit of USD 141.72 million a year earlier.
- Revenue fell as manufacturing and quality system enhancements following the 2025 Reykjavik FDA inspection constrained product availability.
- Product and service revenue dropped 48% to USD 105.94 million, mainly from AVT02 and AVT04 sales through commercialization partners.
- License and other revenue rose to USD 105.7 million on development and regulatory milestones across the pipeline.
- Higher finance costs and sharply lower fair-value gains in finance income weighed on results; cash and equivalents ended at USD 142.8 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-057988), on August 19, 2026, and is solely responsible for the information contained therein.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Trade now！
You may also like
Crypto prices
More
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now